State Street
ANAB icon

State Street’s AnaptysBio ANAB Stock Holding History

State Street’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55M Sell
992,445
-61,029
-6% -$3.28M ﹤0.01% 1686
2025
Q4 		$51.1M Buy
1,053,474
+180,042
+21% +$7.02M ﹤0.01% 1733
2025
Q3 		$26.7M Buy
873,432
+52,401
+6% +$1.2M ﹤0.01% 2084
2025
Q2 		$18.2M Sell
821,031
-39,692
-5% -$831K ﹤0.01% 2234
2025
Q1 		$16M Sell
860,723
-425,032
-33% -$7.09M ﹤0.01% 2256
2024
Q4 		$17M Buy
1,285,755
+379,573
+42% +$9.19M ﹤0.01% 2304
2024
Q3 		$30.4M Sell
906,182
-60,670
-6% -$2.07M ﹤0.01% 1969
2024
Q2 		$24.2M Sell
966,852
-240,552
-20% -$5.6M ﹤0.01% 2077
2024
Q1 		$27.2M Buy
1,207,404
+763,057
+172% +$18.1M ﹤0.01% 2040
2023
Q4 		$9.52M Sell
444,347
-489,015
-52% -$8.43M ﹤0.01% 2619
2023
Q3 		$16.8M Sell
933,362
-279,452
-23% -$5.33M ﹤0.01% 2268
2023
Q2 		$24.7M Buy
1,212,814
+62,867
+5% +$1.27M ﹤0.01% 2118
2023
Q1 		$25M Buy
1,149,947
+48,766
+4% +$1.19M ﹤0.01% 2074
2022
Q4 		$34.1M Sell
1,101,181
-170,546
-13% -$4.82M ﹤0.01% 1889
2022
Q3 		$32.4M Buy
1,271,727
+115,846
+10% +$2.72M ﹤0.01% 1895
2022
Q2 		$23.5M Buy
1,155,881
+197,786
+21% +$4.38M ﹤0.01% 2141
2022
Q1 		$23.7M Buy
958,095
+85,786
+10% +$2.6M ﹤0.01% 2274
2021
Q4 		$30.3M Sell
872,309
-94,558
-10% -$3M ﹤0.01% 2170
2021
Q3 		$26.2M Sell
966,867
-315,243
-25% -$8M ﹤0.01% 2279
2021
Q2 		$33.2M Sell
1,282,110
-479,405
-27% -$11.5M ﹤0.01% 2145
2021
Q1 		$38M Buy
1,761,515
+545,939
+45% +$13.8M ﹤0.01% 1944
2020
Q4 		$26.1M Buy
1,215,576
+21,980
+2% +$534K ﹤0.01% 2074
2020
Q3 		$17.6M Sell
1,193,596
-242,680
-17% -$4.38M ﹤0.01% 2112
2020
Q2 		$32.1M Sell
1,436,276
-519,280
-27% -$9.49M ﹤0.01% 1730
2020
Q1 		$27.6M Buy
1,955,556
+10,547
+0.5% +$160K ﹤0.01% 1639
2019
Q4 		$31.6M Buy
1,945,009
+854,029
+78% +$20.2M ﹤0.01% 1826
2019
Q3 		$38.2M Buy
1,090,980
+133,481
+14% +$6.35M ﹤0.01% 1628
2019
Q2 		$54M Sell
957,499
-41,530
-4% -$2.99M ﹤0.01% 1440
2019
Q1 		$73M Sell
999,029
-122,888
-11% -$8.48M 0.01% 1221
2018
Q4 		$71.6M Buy
1,121,917
+15,185
+1% +$1.13M 0.01% 1116
2018
Q3 		$110M Sell
1,106,732
-194,689
-15% -$16.2M 0.01% 1005
2018
Q2 		$92.5M Buy
1,301,421
+343,771
+36% +$28.8M 0.01% 1095
2018
Q1 		$99.7M Buy
957,650
+311,916
+48% +$35.2M 0.01% 1009
2017
Q4 		$65M Buy
645,734
+517,815
+405% +$38.1M 0.01% 1268
2017
Q3 		$4.47M Buy
127,919
+53,086
+71% +$1.43M ﹤0.01% 2849
2017
Q2 		$1.79M Buy
74,833
+38,996
+109% +$980K ﹤0.01% 3178
2017
Q1 		$995K Buy
+35,837
New +$835K ﹤0.01% 3263

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

State Street's ANAB Position: Q1 2026 in Review

State Street reduced its AnaptysBio (ANAB) stake by 5.8% in Q1 2026, selling an estimated $3.28M and leaving 992,445 shares worth $55M. The position accounts for ﹤0.01% of the portfolio, ranked #1686.

State Street first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $110M in Q3 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • State Street held 992,445 shares of AnaptysBio worth $55M as of Q1 2026.
  • State Street sold 61,029 AnaptysBio shares in Q1 2026, an estimated $3.28M.
  • AnaptysBio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1686 holding.
  • State Street first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
  • State Street's AnaptysBio position peaked at $110M in Q3 2018.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.